Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: lactose monohydrate; hyprolose; magnesium stearate; croscarmellose sodium; microcrystalline cellulose; titanium dioxide; hypromellose; triacetin - dasatinib is indicated for the treatment of adults aged 18 years or over with: ? newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. ? chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukaemia with resistance or intolerance to prior therapy including imatinib. ? newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy. ? philadelphia chromosome positive acute lymphoblastic leukaemia with resistance or intolerance to prior therapy.,dasatinib is indicated for the treatment of paediatric patients with: ? ph+ cml in the chronic phase. ? newly diagnosed ph+ all in combination with chemotherapy.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - filgrastim, quantity: 600 microgram/ml - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 80; sodium hydroxide; sorbitol; water for injections - to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs in doses not usually requiring bone marrow transplantation. to reduce the duration of neutropenia and clinical sequelae in patients undergoing induction and consolidation chemotherapy for acute myeloid leukaemia. for the mobilisation of autologous peripheral blood progenitor cells alone, or following myelosuppressive chemotherapy, in order to accelerate neutrophil and platelet recovery by infusion of such cells after myeloablative or myelosuppressive therapy in patients with nonmyeloid malignancies. for the mobilisation of peripheral blood progenitor cells, in normal volunteers, for use in allogeneic peripheral blood progenitor cell transplantation. in patients receiving myeloablative chemotherapy, to reduce the duration of neutropenia and clinical sequelae following autologous or allogeneic bone marrow transplantation. for chronic administration to increase neutrophil counts and to reduce the incidence and duration of infections in patients with severe chronic neutropenia. in patients with hiv infection, for reversal of clinically significant neutropenia and subsequent maintenance of adequate neutrophil counts during treatment with antiviral and/or other myelosuppressive medications.

Իսրայել - անգլերեն - Ministry of Health

teva pharmaceutical industries ltd, israel - diltiazem hydrochloride - tablets - diltiazem hydrochloride 60 mg - diltiazem - diltiazem - calcium channel blocker for the treatment of angina pectoris.

Իսրայել - անգլերեն - Ministry of Health

teva pharmaceutical industries ltd, israel - epinephrine - solution for injection - epinephrine 1 mg/ml - epinephrine - epinephrine - adrenaline teva solution for injection is indicated in the following situations:– spasm of the airways in acute asthma attacks.– rapid relief of allergic reactions to drugs or other substances.– emergency treatment of anaphylactic shock.– cardiac arrest and cardiopulmonary resuscitation (physical measures should be used first).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - pregabalin, quantity: 300 mg - capsule, hard - excipient ingredients: mannitol; pregelatinised maize starch; purified talc; titanium dioxide; gelatin; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. pregabalin is indicated for the treatment of neuropathic pain in adults

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - pregabalin, quantity: 150 mg - capsule, hard - excipient ingredients: mannitol; pregelatinised maize starch; purified talc; titanium dioxide; gelatin; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. pregabalin is indicated for the treatment of neuropathic pain in adults

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - pregabalin, quantity: 75 mg - capsule, hard - excipient ingredients: mannitol; pregelatinised maize starch; purified talc; titanium dioxide; gelatin; iron oxide red; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. pregabalin is indicated for the treatment of neuropathic pain in adults

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - pregabalin, quantity: 25 mg - capsule, hard - excipient ingredients: mannitol; pregelatinised maize starch; purified talc; titanium dioxide; gelatin; iron oxide yellow; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - pregabalin is indicated for the treatment of neuropathic pain in adults. pregabalin is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.

Իսրայել - անգլերեն - Ministry of Health

teva israel ltd - simvastatin - tablets - simvastatin 20 mg - simvastatin - simvastatin - coronary heart disease : in patients with coronary heart disease and hypercholesterolemia simvastatin-teva is indicated to: - reduce the risk of total mortality by reducing coronary death - reduce the risk of non-fatal myocardial infarction - reduce the risk for undergoing myocardial revascularization procedures. - reduce the risk of stroke and transient ischemic attacks (tia). hyperlipidemia: simvastatin-teva is indicated as an adjunct to diet to reduce elevated total-c ldl-c apo b and tg and to increase hdl-c in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (frederickson types iia and iib) simvastatin-teva therefore lowers the ldl-c/hdl-c and the total-c/hdl-c ratios. homozygous familial hypercholesterolemia: simvastatin-teva is also indicated as an adjunct to diet and other non-dietary measures in reducing elevated total cholesterol ldl-cholesterol and apolipoprotein b in patients with homozygous familial hypercholesterolemia when response to these measures is inadequate. hypertriglyceridemia (fredrickson type iv hyperlipidemia). simvastatin-teva is indicated for the treatment of patients with primary dysbetalipoproteinemia (fredrickson type iii hyperlipidemia).